Related Experiment Video
Updated: Dec 10, 2025
Assessment of de novo Protein Synthesis Rates in Caenorhabditis elegans
Published on: September 12, 2020
Preliminary Data of a Quantitative Point of Care Test for SARS-CoV-2 Antibodies From Greece
Paraskevi C Fragkou1, Vassiliki Papaevangelou2, Anastasia Antoniadou1
1Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Background:
Antibody testing is necessary to identify immune individuals in the post-initial wave of the COVID-19 pandemic.
Patients And Methods:
We prospectively evaluated the performance of a quantitative point-of-care test (POCT) for SARS-CoV-2 antibodies. The patient group (PG) comprised of hospitalized confirmed COVID-19 cases. Asymptomatic healthcare volunteers with negative rRT-PCR were included in the control group (CG). Measurement of IgM and IgG was obtained by dry fluorescence immunoassay.
Results:
Twenty-six PG (65.9±15.4 years old, male 57.7%) and 18 CG (45.6±10.1 years old, male 33.3%) were included. By manufacturer's cut-off (≥0.04 mIU/ml), sensitivity and specificity were 73.08% and 88.89% for IgM and 88.46% and 33.33% for IgG, respectively. Estimated areas under the ROC curve were 0.907 and 0.848 for IgM and IgG, respectively. Results were improved using a cut-off of IgM ≥0.05 mIU/ml and IgG ≥0.10 mIU/ml.
Conclusion:
Using stringent cut-off values, SARS-CoV-2 antibody POCT detects immune people and can be used during socioeconomic normalization of communities.
